Home > Insider Trading > Filing (0000769993-15-001055)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492674	T2 Biosystems Inc.	TTOO	Surgical & Medical Instruments & Apparatus (3841)	204827488

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1477767	J. Thomas Carella	C/O Goldman, Sachs &Amp; Co. 200 West Street New York NY 10282		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-12-09	700,000	$9.75	4,157,240	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock options (Right to buy)	$18.59		2025-06-19	17,647	17,647	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2025-06-19	17,647	17,647	Indirect

Footnotes

The Reporting Person is a managing director of Goldman, Sachs & Co. ("Goldman Sachs"). Goldman Sachs is a wholly owned subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any.
In connection with the closing of a follow-on public offering (the "Offering") of Common Stock, par value $0.001 per share (the "Common Stock") of T2 Biosystems, Inc. which occurred on December 9, 2015, certain investment entities (the "GS Funds"), purchased an aggregate of 700,000 shares of Common Stock at the Offering price of $9.75 per share of Common Stock.
GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock by reason of the direct beneficial ownership of Common Stock by certain of the GS Funds because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs is a wholly owned subsidiary of GS Group. Goldman Sachs is the investment manager of certain of the GS Funds.
The stock options vest and become exercisable in 12 substantially equal monthly installments commencing June 19, 2015. The Reporting Person has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group.